Cite
HARVARD Citation
Das, A. et al. (n.d.). P-304Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less. Annals of oncology. p. . [Online].